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Abstract
The hypoxia and proliferation index increase with grade in human glial tumors, but there is no agreement whether
either has prognostic importance in glioblastomas. We evaluated these end points individually and together in
16 de novo human glioblastomas using antibodies against the 2-nitroimidazole hypoxia detection agent EF5 and
the proliferation detection agent Ki-67. Frozen tumor tissue sections were fluorescence-stained for nuclei (Hoechst
33342), hypoxia (anti-EF5 antibodies), and proliferation (anti-Ki-67 antibodies). EF5 binding adjacent to Ki-67+ cells,
overall EF5 binding, the ratio of these values, and the proliferation index were evaluated. Patients were classified using
recursive partitioning analysis and followed up until recurrence and/or death. Recursive partitioning analysis
was statistically significant for survival (P = .0026). Overall EF5 binding, EF5 binding near Ki-67+ cells, and prolifera-
tion index did not predict recurrence. Two additional survival analyses based on ratios of the overall EF5 binding
to EF5 binding near Ki-67+ cells were performed. High and low ratio values were determined by two cutoff points:
(a) the 50% value for the ratio [EF5/Ki-67Binding]/[Tumorbinding] = RatioEF5 50% and (b) the median EF5 value (75.6%) of
the ratio [EF5/Ki-67Binding]/[Tumorbinding] = Ratiopatients median. On the basis of the RatioEF5 50%, recurrence (P = .0074)
and survival (P= .0196) could be predicted. Using the Ratiopatients median, only survival could be predicted (P= .0291).
In summary, patients had a worse prognosis if the [EF5/Ki-67Binding]/[Tumorbinding] ratio was high. A hypothesis for the
mechanisms and translational significance of these findings is discussed.
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Introduction
Glioblastoma (GB) is one of the deadliest of human cancers, charac-
terized by a 12- to 14-month median survival in patients treated with
surgery, radiation, and temozolomide [1]. There is extensive ongoing
research on the mechanism(s) of this dismal prognosis, including the
role of signaling molecules, cytokines, and drug-modifying enzymes
[2]. Several of these factors are modulated by hypoxia, leading to sub-
stantial clinical and experimental interest in this subject [3]. Hypoxia
is present in many tumor sites including cervix, head and neck, pros-
tate, bladder, pancreas, and soft tissue sarcomas (for review, see Evans
and Koch [4]). Hypoxia has also been shown to affect the efficacy of
chemotherapy [5]. In some tumor types (cervical cancer, sarcomas),
it is associated with tumor aggression, for example, hypoxic tumors
Address all correspondence to: Sydney M. Evans, VMD, University of Pennsylvania, De-
partment of Radiation Oncology, 195 John Morgan Bldg, 37th St and Hamilton Walk,
Philadelphia, PA 19104-6072. E-mail: sydevans@mail.med.upenn.edu
1This study was supported by National Institutes of Health grants RO1 CA 75285,
RO1 CA 113561, and R21 CA 93007 (to S.M. Evans, PI).
Received 4 September 2009; Revised 14 December 2009; Accepted 15 December 2009
Copyright © 2010 Neoplasia Press, Inc. All rights reserved 1944-7124/10/$25.00
DOI 10.1593/tlo.09265
www.transonc.com
Trans la t iona l Onco logy Volume 3 Number 3 June 2010 pp. 160–169 160
are more likely to invade and/or metastasize [6,7] as a result of up-
regulation of proteins such as matrix metalloproteinase, vascular endo-
thelial growth factor, and BCL-XL [6–8]. We have previously reported
on the presence and level of hypoxia in a series of brain tumors of varying
histologic diagnosis, demonstrating that the level of hypoxia increases
with tumor aggressiveness [9]. However, tissue PO2 has never been dem-
onstrated to be a predictive factor in the outcome of patients with GB.
Proliferation, another well-studied physiologic process in tumors, re-
mains controversial as to its prognostic significance in GBs [10–12].
EF5 is a 2-nitroimidazole drug that is administered intravenously
to patients approximately 24 hours preceding surgery. It covalently
binds to hypoxic cells at a rate that is inversely proportional to tissue
PO2 [13,14]. Analytical methods using highly specific, fluorescent
monoclonal antibodies against EF5 adducts have been developed,
calibrated to in vitro controls, and validated, allowing the quantifica-
tion of tissue oxygen levels and the production of tissue oxygen maps
[15]. Immunohistochemical (IHC) studies have generally reported
an inverse spatial relationship between hypoxic and proliferating cells
[16,17], but we noticed that proliferating (Ki-67–positive [Ki-67+])
cells could be found in regions of high EF5 binding in many human
GB tissue sections (Figure 1). This has been previously observed in
liver metastases [18]. On the basis of our observation of colocaliza-
tion of hypoxic and proliferating cells, we developed quantitative
methods using frozen tissue sections to analyze the cellular PO2 from
tissue sections in the region immediately surrounding any defined
anatomic structure (e.g., blood vessels [19] or individual cells [pres-
ent studies]). Herein, we describe the development and application
of such algorithms to quantitatively assess EF5 binding in the region
of Ki-67+ cells. We hypothesized that tumors with many prolifer-
ating hypoxic cells would be more biologically aggressive, perhaps
due to the up-regulation of invasion and metastasis-causing cyto-
kines. In this pilot study, we provide data supporting that the EF5
binding level surrounding proliferating cells, expressed as a ratio
[EF5/Ki-67binding]/[Tumorbinding], is a significant predictor of patient
outcome. We also showed that this ratio variable can independently
predict these end points beyond the recursive partitioning analysis
(RPA) classification [20]. (The RPA classification is based on both
pretreatment patient and tumor characteristics and treatment-related
variables, and it has been shown to be associated with survival du-
ration.) Measurement of the relationship between hypoxia and pro-
liferation in GBs is not likely to be directly applicable to clinical
practice using the complex methods described herein. However, these
techniques should inform the biology and pathophysiology of GBs
for future investigations as well as aid the development of molecular
and imaging theragnostics.
Materials and Methods
The Institutional Review Board of the University of Pennsylvania
Clinical Trials and Scientific Monitoring Committee (Abramson
Cancer Center) and the Cancer Therapeutics Evaluation Program
of the National Cancer Institute approved this prospective trial of
EF5. All patients signed a consent form for both the study and for
privacy (Health Insurance Portability Accountability Act). Patients of
all ethnic and sex groups were included. Eligible patients were those
undergoing resection of a brain mass assessed as likely be a neoplasm
based on imaging appearance. Exclusion criteria included patients
with a history of grade 3 or 4 peripheral neuropathy [21], pregnant
or nursing patients, and patients younger than 18 years.
EF5 Administration
The National Cancer Institute, Division of Cancer Treatment, sup-
plied EF5 in 100-ml vials containing an aqueous solution of 3 mg/ml
EF5 plus 5% dextrose and 2.4% ethanol. EF5 was administered
through a peripheral intravenous catheter approximately 24 hours be-
fore surgery at a rate no greater than 350 ml/h and to a total dose of
Figure 1. Examples of EF5, Ki-67 (proliferation), and Hoechst 33342 (viable cells) binding in GBs. Color codes: hypoxia (EF5 binding, red),
viable cells (Hoechst 33342, blue) and proliferation (Ki-67, green). Left panel: patient 39; right panel: patient 55. Both patients have
regions of moderate hypoxia, but in patient 39, all proliferating cells are in oxic regions compared with patient 55, where proliferating
hypoxic cells are seen. It should be noted that yellow cells in this image are moderately hypoxic and proliferating, but many proliferating
cells close to the moderately hypoxic regions are mildly hypoxic.
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21 mg/kg. Blood samples for drug levels were obtained before (con-
trol), 1 hour after drug administration, and at the time of surgery. Cal-
culation of the drug concentration integrated with respect to time (area
under the curve, AUC) was used to correct the absolute EF5 tissue
binding level (IHC) for variations in drug dose and drug exposure time
between patients [22].
Tissue Acquisition, Processing for EF5 Binding, and Analysis
of EF5 Images
On the day after EF5 administration, tumors were surgically re-
sected and placed in sterile, iced EXCELL 610 medium ( JRH Bio-
sciences, Lenexa, KS). In collaboration with the pathologist, tissue
samples deemed unnecessary for clinical diagnosis were taken to
the laboratory for processing and analysis.
IHC staining methods and quantitative fluorescence microscopy of
EF5 in in situ tumor sections (Figure 1) and EF3 in tissue cubes for
cube reference binding (CRB) were performed as reported previously
[23]. CRB determination is an in vitro technique where millimeter-
sized tissue cubes taken from an individual patient’s tumors were in-
cubated at 600 μM/h in EF3, a sister drug of EF5, under controlled
hypoxic conditions. The goal of this procedure was to determine the
maximum level of EF3 binding possible for each patient’s tumor. This
technique allowed normalization of the in situ EF5 binding to each
tumor’s maximum binding value after correction for the AUC
[22,23]. In addition to staining for EF5 alone, adjacent tissue sections
were 1) costained for EF5 and Ki-67 (called EF5/Ki-67), as previously
reported [24] (Figure 1), and 2) stained with “Competed Stain” (anti-
body mixed with 0.5 mM authentic EF5) to account for fluorescence
due to nonspecific staining (data not shown). The latter value was sub-
tracted from the calculated value of in situ EF5 binding.
Images were analyzed using routines written in MatLab (The
MathWorks, Inc, Natick, MA), whereby EF5-dependent fluores-
cence intensity values were sampled within an image (or part thereof )
based on intact (viable) nuclei identified by a Hoechst 33342 mask
[19] (Figure 2). Hoechst 33342 was applied to the slide immediately
preceding imaging to stain the nuclei. The final EF5 intensity values
were corrected for lamp intensity, individual patient AUC, and the
competed stain value. The result of these corrections provided an
EF5 binding value for each pixel, expressed as a percent of CRB
(%CRB) [8,23]. We have converted %CRB into tissue PO2 ranges
using extensive data from in vitro studies [9,13,23,25].
To further characterize the image, cumulative frequency histo-
grams of the %CRB of all the pixels in the image were calculated.
Using this terminology, the median binding would be CF50. To
emphasize the most hypoxic cells, we used the CF95 value, wherein
95% of the cells have lower values and 5% have higher values. Thus,
CF95 = 20% would mean that 95% of the EF5 values in the image
were at or below 20% of maximum EF5 binding.
Proliferation Analysis
All images were loaded, preprocessed, and analyzed based on
Hoechst 33342 and EF5/Ki-67 images for each tissue section (Fig-
ure 2). To correct for small misalignments due to wavelength shifts,
the EF5/Ki-67 images were each aligned to the Hoechst 33342 image.
The Hoechst 33342 image was masked to reduce background
noise using the Imtophat method (MatLab; The MathWorks, Inc).
A threshold was applied to eliminate all pixels with an intensity value
Figure 2. Analysis of EF5 value surrounding Ki-67+ cells: The upper left image depicts nuclei stained with Hoechst 33342 (the same
process is done using Ki-67–stained cells, not shown). The upper central image is the point map that results from the counting algorithm
described in text. A similar map is generated from the Ki-67 image (not shown). The upper right image shows the correlation between
the counted points and the original Hoechst 33342 image. The mask shown in the lower left is generated from the upper left and middle
images using the identified nuclei as reference points for cells and the base Hoechst image to threshold against. In combination, this
yields an accurate map of viable tissue regions. The lower middle image shows the EF5 image after calibration and a Gaussian blur to
eliminate hard edges and maintain the overall binding levels. The lower right image shows the combination of all images: the tissue
mask has been applied to eliminate off tissue areas (black), calibrated EF5 binding levels are shown in varying intensities of red, green
dots are Ki-67+ cells, and the blue rings are the 50-μm regions around these cells in which the PO2 levels are calculated.
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below 0.005, yielding a black-and-white image mask. The resulting
image was repeatedly (up to 1000 times) morphed with a majority
transformation that turns any black pixel surrounded by five or more
white pixels to white. This step filled in small areas that may have
been missed by the previous threshold. The masks were reviewed in-
dividually at the end of the process to ascertain that the process
was successful in capturing the features of the Hoechst 33342 image
(Figure 2).
A counting algorithm was then applied to the EF5/Ki-67 and
Hoechst 33342 images to identify each cell and to determine accu-
rate counts of the number of total cells and of proliferating cells. To
eliminate background values, the Imtophat filter was applied to both
images. Each cell was identified in an iterative process. Each iteration
included identification, centralization, and hole-punching steps (Fig-
ure 2). Identification was achieved by applying a threshold to the
image that was at first highly discriminating and was gradually re-
duced in a quadratic fashion to a preset minimum value determined
through repeated experimentation. Each of the identified objects was
then “shrunk” to a point using a centralization process resulting in
the replacement of the cell with a single pixel located at its centroid
(center of mass). The hole punch completed the iteration, whereby
the original image had a cell-sized (15 μm) disk centered on each
centralized identified point removed from future iterative steps. This
process resulted in a highly accurate cell count, as determined by
hand counting in small areas (data not shown). The procedure used
30 iterations, with an initial threshold value of 1.00 decreasing to
0.03 in a quadratic fashion. These steps resulted in two new images
termed point maps, one for Hoechst 33342 and one for the Ki-67
aspect of the EF5/Ki-67 images (Figure 2).
After the Hoechst 33342 and Ki-67 point maps were created, the
correspondence between each Ki-67+ object and exactly one Hoechst
33342-identified nucleus was checked, for example, to confirm that
the Ki-67–labeled objects were a strict subset of Hoechst 33342–
labeled objects. To do this, we relied on the fact that the two point
maps were generated from aligned images of the same tissue piece.
A final point map was generated from the Hoechst 33342 point
map where, for each Ki-67 point, the nearest Hoechst 33342 point
was tagged as Ki-67+ (Figure 2). If a Ki-67+ point was not within
15 μm (roughly the size of a cell), then it was assumed that the
anti-Ki-67 antibody had caused an artifact, which was then elimi-
nated. This was found to be less than 1% of the cells examined (data
not shown). Using this point map, our goal was to obtain informa-
tion about the tissue oxygen level in the immediate vicinity of each
Ki-67+ object. However, signal from the anti-Ki-67 was often very
strong, and despite using a different fluorescent color to quantify
EF5 binding, there was some bleed through from the Ki-67 dye
(Cy3 vs Cy5, respectively). This represented a substantial signal in
regions of low EF5 binding because EF5 binding is quantified over
an intensity range spanning several decades [25]. To eliminate the
Ki-67 fluorescence from calculation of the EF5 fluorescence sur-
rounding the Ki-67+ cells, the fluorescence in the central regions
of the area surrounding these cells was removed from analysis. Spe-
cifically, EF5 binding was assessed in a donut-shaped region centered
on each Ki-67+ nucleus, with the central hole 15 μm in diameter
and the overall diameter as 50 μm, excluding any pixels eliminated
by the overall tissue mask (Figure 2).
The average EF5 value for the entire image (minus the center of
the “donuts”) was calculated based on the overall tissue mask. Cumu-
lative frequency graphs of EF5 binding in the tissue section being
evaluated versus near Ki-67+ cells was determined based on the
95th percentile of EF5 binding (CF95). Final analyses were based
on the CF95 values for the brightest slide evaluated for each patient
as in our previously published studies [15,26,27].
Pathological Examination
All tissue sections were reviewed by a neuropathologist to confirm
that the tissue section contained tumor. Tissue sections that con-
tained less than 20% viable tumor or more than 80% normal tissue
or necrosis were eliminated from further analysis. A minimum of
three tissue sections from each patient was examined. The histologic
diagnosis of the tumor in the EF5-stained tissue sections was com-
pared with the pathologic diagnosis based on paraffin-embedded tissue
sections. None of the EF5-stained tissue sections received a diagno-
sis that differed from that rendered clinically. A minimum of three
tumor sections stained for EF5 and EF5/Ki-67 was examined for
each patient.
Tumor Staging and Patient Outcome
The World Health Organization grade was based on pathological
examination of the surgical specimen. Recurrence was determined by
the treating physician based on magnetic resonance imaging studies
(usually a change over time) and/or the examination of a pathological
specimen from surgical re-resection or biopsy.
Statistical Methods
Descriptive statistics (frequency, percentage, mean, and SD) were
used to report distributions of patient and tumor variables. Time to
recurrence was defined from the date of EF5 administration (1 day
preceding surgery) to the date of a documented event (recurrence
or death due to any cause) or censored at last patient contact. For
patients in whom a gross total resection was not obtained, time
to recurrence was defined as the point at which tumor progression
(i.e., growth) was identified on imaging. In two patients (nos. 32
and 58), the recurrence date could not be confirmed, so for analysis
the date of recurrence was taken as the date of death. Overall survival
was defined from the date of EF5 administration (1 day preceding
surgery) or censored at the last patient contact. Potential prognos-
tic factors considered in this analysis were the RPA classification
[20,28], proliferation index (PI), EF5 (CF95) binding in the vicinity
of Ki-67+ cells, EF5 binding in the brightest tissue section examined
(CF95 max), and a ratio of the latter two values. Survival analysis of
the ratio were based on two cutoff points: (a) the 50% EF5 value
for the ratio of [EF5/Ki-67binding]/[Tumorbinding] (RatioEF5 50%) and
(b) the Ratiopatients median value (=75.6%; Table 1).
The distributions of time to event outcomes were estimated by the
method of Kaplan and Meier [29] and compared among patient
groups defined by a prognostic factor using log-rank tests [30].
The independent prognostic value of a factor was evaluated using a
multivariate Cox proportional hazards model [31]. Statistical signif-
icance was defined as P < .05. Borderline significance was defined as
less than 0.10.
Results
Between September 2000 and November 2005, 17 patients with pre-
viously untreated GB (World Health Organization grade 4 gliomas)
were entered into this clinical trial of EF5. One patient deteriorated
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rapidly postoperatively and died of non–brain tumor–related causes
preceding the onset of radiation therapy; this patient was not included
in the analysis. Of the 16 remaining patients, 15 had died and 1 pa-
tient (no. 115) remained alive and without recurrence at the time of
analysis. The patients’ demographics and the details of their tumors
and treatments are summarized in Table 2. The patients’ mean age
was 56.9 years (range, 23-77 years), with 12 males and 4 females. Fif-
teen patients were white and one patient was African American. There
were 3, 9, and 4 patients with RPA levels of 3, 4, and 5, respectively
(Table 2). Survival analysis confirmed that RPA classification was pre-
dictive of patient survival in this group of patients (RPA 3 and 4 vs
RPA 5, P = .0026). Despite the small number of patients included
in this trial, this finding confirms that these 16 patients are generally
representative of patients with de novo GBs reported in the literature
[28]. All patients received surgery with the intent of gross total resec-
tion followed by external beam radiation therapy (Table 2). In three
patients, the actual radiation prescription could not be determined, al-
though notes from the outside hospitals confirmed that full-course
radiation therapy had been administered. In four patients, additional
radiation was given at the time of recurrence by iodine 125 (125I)
monoclonal antibody treatment (n = 1) or Gliasite balloon (n = 3;
Table 2). Administration of adjuvant therapy (chemotherapy, hor-
monal, or molecular therapy) either during or after initial radiation
therapy or at the time of recurrence could be confirmed in 13 of 16 pa-
tients. Two patients received no adjuvant therapy, and this information
was not available in one patient. Temozolomide, either during and/or
after radiation, was administered in 11 patients. There was no relation-
ship between temozolomide administration and outcome in this small
patient group (P > .05).
All 16 gliomas contained regions of hypoxia, although the level and
extent of hypoxia varied considerably between patients. As shown
in Table 3, the most hypoxic region, CF95 max in the 16 GBs ranged
from 3.2% (mild hypoxia, PO2 ≈ 2.5%) to 26.7% (moderate hypoxia,
PO2 ≤ 0.5%). On the basis of these data, most of the tumor cells in
any of these tumors were at intermediate or high O2 levels, and all
tumors contained many cells that were physiologically oxic. When
analysis of patient outcome was performed based on the CF95 max of
EF5-alone–stained sections, this value was not predictive for either tu-
mor recurrence or patient survival (P > .05).
Tissue sections were also costained with EF5/Ki-67 and analyzed
for both PI and the EF5 values surrounding Ki-67+ cells (Figure 1
and Table 3). The PIs in this group of GBs ranged from 1.3% to
15.5% (median, 5%). Results of the survival analysis based on the
PI or the EF5 values surrounding Ki-67+ cells were not significant
for either recurrence or survival (P > .05).
As described above, two cutoff points were tested for evaluating
the predictive value of the [EF5/Ki-67binding]/[Tumorbinding] ratio: (a)
RatioEF5 50% (4 patients below CF95 = 50% and 12 patients above
Table 2. Patient Demographics, Tumor Characteristics, and Treatment Modalities.
Patient ID Age/Race/Sex Tumor Location RPA Classification Total Resection Radiation Dose (Gy)* Adjunctive Chemotherapy
50 48/W/M R parietal 3 Y 6120, 125I MAB T, CCNU, Gliadel
115 50/AA/F Parietal 4 N 6000 Irinotecan, LdT
39 49/W/M R temporal 4 Y 6000 TAM, T
38 48/W/M R temporal 3 Y 6000, Gliasite† Gliadel
33 73/W/M R temporal 4 Y 6100 T
74 69/W/F R parietal 5 N 6000 T, LdT
42 67/W/F R frontal 4 N 5940 T, TAM
55 52/W/M L parietal 4 Y 5940 T, LdT
127 52/W/M L > R corpus callosum 5 N RDNR INA
57 23/W/M L frontal 3 Y 6000, Gliasite† T, LdT
101 70/W/M R temporal-occipital 5 Y RDNR T, LdT
123 55/W/M R temporal-parietal 4 Y 6000, Gliasite† T, LdT, CPT11, Avastin
52 77/W/M L temporal 4 Y 6000 None given
107 51/W/F R temporal 4 N 6000 T, LdT, CPT11, BMS
32 55/W/M L parietal 5 N RDNR TAM
58 71/W/M Corpus callosum 4 N 5940 None given
BMS indicates BMS-247550 (ixabepilone);CCNU, lomustine;CPT11, irinotecan;Gliadel, wafers impregnatedwith bis-chloronitrosourea (Carmustine); INA, information not available; LdT, low-dose temodar;
RDNR, radiation dose not recorded because patient was treated at an outside hospital (however, notes confirmed that a full course of treatment was completed); T, temodar; TAM, tamoxifen; W, white.
*External beam.
†Gliasite = 6000 cGy at 1 cm.
Table 1. Ratio Value Definitions and Details.
Ratio Value Based on EF5 Value (RatioEF5 50%)* Ratio Value Based on No. Patients per Group (Ratiopatients median)
†
Cutoff points 50% 75.6%
No. patients below and above cutoff point 4 and 12 8 and 8
Significant for recurrence (univariate)? Yes, P = .0074. The unadjusted hazard ratio is
10.5 (95% CI, 1.3-84.2).
No, P = .17. The unadjusted hazard ratio is 2.2 (95% CI, 0.7-6.8).
Significant for overall survival (univariate)? Yes, P = .0196. The unadjusted hazard ratio is
5.2 (95% CI, 1.1-24.3).
Yes, P = .038. The unadjusted hazard ratio is 3.4 (95% CI, 1.1-11.0).
Significant for overall survival among RPA = 3 and
4 patients (univariate)?‡
Yes, P = .048. The unadjusted hazard ratio is
4.4 (95% CI, 0.9-21.1).
Borderline, P = .059. The unadjusted hazard ratio is 3.4
(95% CI, 0.89-13.3).
Significant for overall survival in multivariate analysis
with RPA?
Yes, P = .038 Borderline, P = .09
*RatioEF5 50% = see text; note, based on brightest tissue section for each patient.
†Ratiopatients median = see text; note, based on brightest tissue section for each patient.
‡n = 12, owing to elimination of patients with RPA = 5 from the analysis.
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CF95 = 50%) and (b) Ratiopatients median (75.6%; 8 patients above and
below this value) (Tables 1 and 3). Using the variable RatioEF5 50%,
patients had a better prognosis if the ratio was less than 50%. This
discriminator was predictive of both time to recurrence (P = .0074;
Figure 3 and Table 1) and overall survival (P = .0196) (Figure 4A
and Table 1). When considered along with RPA classification for over-
all survival (recurrence was not tested because RPA is not predictive of
recurrence), the RatioEF5 50% was found to be an independent prog-
nostic factor (P = .038).
Using Ratiopatients median as a discriminator, there was no predictive
value for time to recurrence (P = .17; Table 1), but it was predictive
for overall survival (P = .038) (Figure 4 and Table 1). When consid-
ered along with RPA classification, the Ratiopatients median value was
found to be only borderline in its association with overall survival
(HR = 2.8, P = .09).
Figure 3. Analysis of time to tumor recurrence in 16 newly diag-
nosed GB patients based on their [EF5/Ki-67binding]/[Tumorbinding] ra-
tio. Patients with a RatioEF5 50% less than 50% (n = 4; dotted line)
have a significantly longer time to recurrence than those with a
RatioEF5 50% more than 50% (n = 12; solid line); P = .0074. Using
the cutoff point of Ratiopatients median, this factor was not significant
for recurrence (data not shown).
Table 3. Patient Survival and Recurrence End Point Analyses.
Patient ID Days Surviving Days to Recurrence CF95 max of Tissue Sections Examined, % EF5 Value Near Ki-67+ Cells* (CF95), % Ratio,
† % PI,‡ %
50 677 235 7.9 1.0 12.4 2.8
115§ 1106 1106 5.0 1.5 30.5 2.8
39 1054 938 26.1 10.5 40.5 3.1
38 691 488 6.9 3.2 46.6 15.5
33 227 126 14.0 8.6 61.2 5.3
74 241 137 5.7 3.7 64.1 6.2
42 641 121 19.6 13.3 67.7 6.8
55 831 187 15.1 11.4 75.3 6.0
127 371 100 7.8 5.9 75.9 6.0
57 470 182 17.5 14.1 80.4 2.5
101 190 112 4.2 3.4 81.8 1.3
123 528 117 3.2 2.6 82.3 4.6
52 489 322 26.7 22.7 85.2 4.9
107 700 262 19.3 17.2 89.5 5.1
32 130 130 21.6 19.9 91.9 11.8
58 124 124 5.5 5.3 96.6 2.0
†Ratio = EF5 value near Ki-67+ cells (CF95) / overall EF5 value (CF95 max).
‡PI = number of Ki-67+ nuclei/total number of nuclei stained with Hoechst 33342.
§This patient is still alive without recurrence.
Figure 4. Analysis of time to patient survival in 16 newly diagnosed
GB patients based on their [EF5/Ki-67binding]/[Tumorbinding] ratio. (A)
Patients with a RatioEF5 50% less than 50% (n = 4; dotted line)
have a significantly longer time to recurrence than those with a
RatioEF5 50% more than 50% (n = 12; solid line); P = .0196. (B)
Comparing patients below and above of the Ratiopatients median
value, patients had a significantly longer time to recurrence when
this value was greater than the median (75.6%; n = 6); P = .0291
(dotted line).
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In addition to performing a multivariate analysis, we performed a
univariate analysis of [EF5/Ki-67binding]/[Tumorbinding] ratio values
but only included the RPA class 3 or 4 (n = 12; Figure 5). Although
this further reduces the sample size, the remaining patient subset was
somewhat more homogeneous. This analysis will not answer the ques-
tion of whether [EF5/Ki-67binding]/[Tumorbinding] ratio is an indepen-
dent predictor of RPA but rather whether the predictive ability of this
ratio will hold in patients with RPA = 3 or 4. RatioEF5 50% had a hazard
ratio of 4.4 (95% confidence interval 0.90-21.1) and a significant log-
rank test P = .048. Ratiopatients median, using cutoff point of 75.6%, had
a hazard ratio of 3.4 (95% confidence interval [CI], 0.89-13.3) and a
borderline significant log-rank test (P = .059; Table 1).
Discussion
In this pilot study, we have identified that GBs are characterized by
varying degrees of hypoxia as assessed by EF5 binding and that most
cells in GBs are either oxic or at intermediate levels of hypoxia. We
have previously reported that EF5 binding generally increases with
tumor grade when considering all types and grades of brain tumors
[9,26], in keeping with our former studies in sarcomas [32]. This is
in contrast to our studies in head and neck squamous cell carcinomas
where tumor recurrence was associated with high EF5 binding irre-
spective of tumor grade [15]. Our results in brain tumors are distinct
from previously published studies using Eppendorf needle electrodes
[26,33,34]. We find that virtually all GBs contain some hypoxic re-
gions, in comparison to grade 3 tumors that can contain rare regions
of hypoxia and grade 2 tumors that are essentially oxic. Because our
methods allow quantification of both the extent and degree of tis-
sue hypoxia at a cellular resolution, our most general observation
has been that all types of tumors contain physiologically oxic cells,
with the main clinically relevant difference being the relative fraction
of tissue existing under moderately or severely hypoxic conditions
[15,26,32]. Thus, our central hypothesis has been that tumor ag-
gressiveness is best characterized by the most hypoxic cells present,
and we have substantiated this in sarcomas, head and neck cancers,
and high-grade glial brain tumors [15,26,32]. Our findings confirm
studies in several other tumor types using other hypoxia measure-
ment techniques [35–37]. However, this pilot study demonstrates
that EF5 binding alone was not successful in predicting outcome
for the small number of newly diagnosed GB patients studied herein.
We next considered PI as a means of predicting outcome in pa-
tients with GB. The PI contributes to prognosis for some tumor
types (i.e., breast cancer [38] and squamous cell carcinomas of the
oropharynx [39]) but has not consistently been associated with out-
come in brain tumor patients [10–12]. This inconsistency should
perhaps be expected. Non–cycling cells are known to be resistant
to both chemotherapy and radiotherapy, and hypoxia can cause
cells to exit the cell cycle [40,41]. However, rapid growth can con-
tribute to a lack of tumor control, and it has been suggested that it is
important to characterize a tumor’s growth fraction before protracted
treatments such as radiotherapy [42]. The balance between cell pro-
liferation and death has been noted to be an important factor in de-
termining overall tumor growth, and this consideration makes the
understanding of the role of the PI, in the absence of quantification
of the balancing factor cell death, complex [43].
Despite numerous investigations of hypoxia or proliferation indi-
vidually, little is known about how these combined parameters (their
quantitative and/or spatial relationships) contribute to outcome in
human cancer. Several studies have combined analysis of endogenous
markers of hypoxia in combination with proliferation markers in hu-
man cancers. One of the advantages of using endogenous hypoxia-
associated markers (carbonic anhydrase 9, hypoxia-inducible factor 1,
glucose transporter 1, and vascular endothelial growth factor) is that
large retrospective studies using banked materials can be performed.
However, all of these markers are known to measure factors in addi-
tion to tissue PO2 [44]. Despite the expectation that proliferation
would decrease with hypoxia, Saarnio et al. [45] showed expression
of CA9 in areas of colorectal neoplasms with high proliferative ca-
pacity. Hoskin et al. [46] studied bladder cancer and found that pro-
liferation was significantly higher in those tumors with the highest
levels (>10%) of both GLUT1 (P = .025) and CA9 (P = .029) com-
pared with those tumors that either were negative or had low levels of
expression; colocalization studies were not performed because of the
requirement to develop complex algorithms and methods. Neither
the endogenous hypoxia markers nor PI (based on Ki-67) predicted
for local control or metastases-free survival in this study. Hoogsteen
et al. [47] studied CA9 and iododeoxyuridine (IdUrd) labeling in bi-
opsies of head and neck squamous cell carcinomas, reporting that
colocalization between IdUrd and CA9 ranged from 0% to 53%.
The interpretation of the data in all of these studies is complicated
by the absence of actual PO2 values to correspond to the regions
stained for endogenous markers. The study of Hoogsteen et al. used
distance from blood vessels as a surrogate for tissue PO2; the fraction
of IdUrd-labeled cells positive for CA9 was highest at an intermediate
distance from the blood vessels (100-150 μm). We have recently re-
ported that in brain tumors, distance from blood vessels is not a good
surrogate for oxygen partial pressure, as measured by EF5 binding
[19]. Nonetheless, the fraction of IdUrd-labeled cells that were also
positive for CA9 in the head and neck cancer study of Hoogsteen
et al. correlated with the worst disease-free survival rates (P = .04).
The latter observation parallels the findings reported herein.
Nordsmark et al. [48] studied tumor oxygenation in human sar-
comas using polarographic oxygen needle electrodes, proliferation,
Figure 5. Multivariate analysis of 16 newly diagnosed GB patients
based on their [EF5/Ki-67binding]/[Tumorbinding] ratio and their RPA
classification. When considered along with RPA classification for
overall survival, RatioEF5 50% was found to be an independent
prognostic factor (P = .038). When considered along with RPA
classification for overall survival, Ratiopatients median was found to
be of borderline significance prognostic factor (P = .09). Dotted
line = RatioEF5 50% < 50%, solid line = RatioEF5 50% < 50%.
166 Hypoxia and Proliferation in Glioblastomas Evans et al. Translational Oncology Vol. 3, No. 3, 2010
and potential doubling time (Tpot) with iododeoxyuridine flow cy-
tometry and IHC. There was a significant correlation between the
median PO2 and the tumor cell potential doubling time (P = .041).
Interestingly, the fastest proliferating tumor cells were found in the
poorest oxygenated soft tissue sarcomas.
Studies have been performed using pimonidazole as a hypoxiamarker
in human colorectal [18], head and neck [17], bladder [16,46], and cer-
vical cancers [49,50]. In some studies, colocalization of pimonidazole
and proliferation markers was found [17,18], and in others, there was
an inverse relationship between these end points [50]. In bladder can-
cers [16], increased vessels in pimonidazole-positive areas and increased
numbers of proliferating cells near these vessels were reported. The
percentage of IdUrd-positive cells in pimonidazole-positive areas were
not associated with survival in head and neck cancer [51].
The RatioEF5 50% was initially selected for analysis because there
was a clear break in the data between patient 38 ([EF5/Ki-67binding]/
[Tumorbinding] ratio = 46.6) and patient 33 (ratio value = 61.2;
Table 3). The selection of a RatioEF5 50% between these values seemed
appropriate in the absence of any comparative data analysis of this type
in the literature. In addition, a cutoff point based on physiologic mea-
surements seemed more meaningful than a statistical value of 50%
of patients above or below a random ratio value (Ratiopatients median;
Table 3). Considering a Ratiopatients median of 75.6%, the values imme-
diately above and below only differ by 0.3 (75.3% and 75.9%). These
are very unlikely to be physiologically different because this difference
is beyond the accuracy of the measurement techniques. Nonetheless,
we present both data sets because the Ratiopatients median is commonly
used in the literature. The results of the analyses of both cut points are
similar although not identical (Table 1).
We find that for the most aggressive tumors (12/16 patients;
EF5EF5 50% > 50%), irrespective of the Ki-67+ fraction and degree
of hypoxia found, there was virtually no overall relationship between
hypoxia and the presence of Ki-67+ cells. That is, the distribution of
EF5 binding around Ki-67+ cells was not different from that of the
rest of the tumor. In contrast, for the less aggressive tumors (4/16;
RatioEF5 50% < 50%), Ki-67+ cells had a distribution of EF5 binding
values that was lower (e.g., these cells were relatively oxic) compared
with the tumor tissue as a whole. The findings were similar when the
Ratiopatients median was considered. The observation related to most
aggressive versus less aggressive tumors represents a subtle difference,
made possible only by the quantitative nature of EF5 binding cal-
culations. The impact of this difference was significant, even using
multiparametric analysis combined with RPA; RatioEF5 50% was a
predictor for tumor recurrence and patient survival in the therapy-
responsive patients. Because of this, we thought it important to bring
these results forward despite the pilot nature of this study. In addi-
tion, the new image analysis methods described herein should be very
useful in the evaluation of EF5-stained tissues or other marker bind-
ing. We propose that this result may help elucidate basic mechanisms
of GB aggressiveness.
Because the methods described in this report are new, we do not
know whether other tumor types will behave like GBs. Indeed, it
is not certain what to expect because there are no previous studies
where proliferation data have been colocalized with the actual PO2 of
Ki-67+ cells.
A characteristic feature of GBs is the presence of infarcted vessels
leading to the phenomenon of pseudopalisading necrosis [52]. If
much of the hypoxia found in GBs were related to these (presum-
ably) irreversible blockages of blood flow, then perhaps the PO2 of
dividing cells reflects the physiological consequences of the pseudo-
palisade formation (i.e., trapping of the cells) rather than a specific
effect on cell cycling. If this were true, then the aggressiveness of the
tumor might relate to the frequency and extent of vessel infarction
leading to a higher probability of trapping cycling cells in these vol-
umes; this may lead to the impression that the PO2 around these cells
was similar to that of the tumor as a whole. Tumor vessel infarction
has been commonly described in GB [52], and abnormalities of the
clotting cascade are not uncommon in patients with any malignant
tumor type, especially in patients with GB. There is an interesting
discussion in the literature arising from the observation of Brat and
van Meier about whether cells actively invade toward or away from
these infarcts. Our observations are more in keeping with the latter.
Currently, an understanding of the factors that cause cells in tu-
mors to exist in a cycling versus noncycling state (proliferative “P” vs
quiescent “Q” [53]) is incomplete. “Q” cells were originally thought
to arise from insufficient supply of cytokines or nutrients, including
oxygen. Data from in vitro studies are not very informative because
cell growth is virtually unaffected by oxygen tensions of 0.2% or even
less (considered as “severe” hypoxia) [40,41,54]. Current thinking
about the cycling status of individual tumor cells would undoubtedly
invoke a multitude of molecular signaling mechanisms affecting many
physiologies in the tumor, as well as that of supporting tissue cells and
tumor stem cells. However, studies of oxygen dependence of such phe-
nomena under carefully controlled and monitored conditions have not
been performed. The data presented in this report emphasize the im-
portance of detailed evaluations on PO2 both in vitro and in vivo. An
important clinical ramification of our results is that there may not be a
consistent or general relationship between absolute PO2 and inhibition
of cell cycling, suggesting that tumor aggressiveness is modulated by
the PO2 dependence of cell cycling in individual tumors. Our observa-
tions and hypotheses are undergoing further testing and study.
In summary, the understanding of why GBs are treatment-resistant
remains poor despite decades of research. The predictive factors cur-
rently in use rely on various clinical and pathological factors deter-
mined in a detailed statistical analysis, for example, RPA [18]. In
many cancers, hypoxia and/or proliferation are documented prognostic
factors but not in GBs. This pilot study identifies a unique interaction
between these factors and seems to show prognostic importance for
recurrence and survival, independent of RPA status. Three translation-
ally relevant insights are provided in this article:
1) Hypoxia is always found in GBs, and therefore, its measure-
ment, treatment targeting, and modification are likely to have im-
portant roles in patient’s evaluation and therapy.
2) Future studies are necessary to identify the mechanisms of the
findings herein, particularly whether they are the result of molec-
ular modifications of tumor metabolism or a temporal vascular
phenomenon. On the basis of these results, specific therapies
might be developed.
3) Future prognostic studies must evaluate the biology (including
molecular) and physiology of individual tumors rather than em-
phasize differences between patient groups.
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